Lincoln Pharmaceuticals Ltd. (BSE: 531633) is a Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹1,095 Cr, it ranks #1,534 by market cap among the 6,137 Indian listed companies on FinBizNet, and #23 of 63 in Pharmaceuticals. At ₹512.70 (as of 25 Oct 2026), the share price is 33.4% below its 52-week high of ₹770.00 and 16.5% above its 52-week low of ₹440.00. The share price is down 2.8% over one year and down 11.6% over three months.
| Current Price | ₹512.70 |
|---|---|
| Market Cap | ₹1,095 Cr |
| BSE Code | 531633 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 12.5 |
| Return on Equity | 12.30% |
| Return on Assets | 6.23% |
| 52-Week Range | ₹440.00 – ₹770.00 |
| 1-Year Price Change | -2.8% |
| 3-Month Price Change | -11.6% |
| Beta (1Y) | 0.3 |
| Dividend Yield | 0.33% |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.lincolnpharma.com |
| Revenue | ₹177 Cr |
|---|---|
| Net Profit | ₹36 Cr |
| Net Margin | 20.4% |
| EPS (Basic) | ₹18.09 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East Asia. Lincoln Pharmaceuticals Limited was incorporated in 1979 and is based in Ahmedabad, India.
1. Phamaceuticals-This segment manufactures and sells pharmaceutical products. It offers products in the areas of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin’s, analgesic, anesthetics, respiratory, anti-pyretic, and GIT, as well as vitamins-minerals and iron preparations. 2. Chemical-This segment distributes chemicals products. 3. Segment Adjustment-0 4. Corporate-0
1. Pharmaceuticals Business-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Lincoln Pharmaceuticals Ltd. | ₹1,095 Cr | 12.5 | 12.30% | ₹177 Cr | -2.8% |
Listed by market capitalisation. Ratios are shown for context only.
Lincoln Pharmaceuticals Ltd. is trading at ₹512.70, with a market capitalisation of ₹1,095 Cr.
Lincoln Pharmaceuticals Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Lincoln Pharmaceuticals Ltd. has a P/E of 12.5 and a return on equity of 12.30%.
Lincoln Pharmaceuticals Ltd. is listed on the BSE under the scrip code 531633.
Lincoln Pharmaceuticals Ltd.'s share price is down 2.8% over one year and down 11.6% over three months. Its 52-week range is ₹440.00 to ₹770.00.
In Q1 FY27, Lincoln Pharmaceuticals Ltd. reported revenue of ₹177 Cr and net profit of ₹36 Cr, with basic EPS of ₹18.09 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.